NCT06297941 - Study of REM-422 in Patients With AML or Higher Risk MDS | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

April 26, 2024

Primary Completion Date

March 15, 2026

Study Completion Date

June 15, 2027

Conditions

Myelodysplastic SyndromesHigher Risk Myelodysplastic SyndromesAcute Myeloid LeukemiaAcute Myeloid Leukemia Refractory

Interventions

DRUG

REM-422

"REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~REM-422 will be administered orally once daily"

Trial Locations (9)

10065

RECRUITING

Memorial Sloan Kettering, New York

33612

RECRUITING

Moffitt Cancer Center, Tampa

77030

RECRUITING

MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope, Duarte

02114

RECRUITING

Massachusetts General Hospital, Boston

Unknown

RECRUITING

Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux

RECRUITING

AP-HP - Hôpital Saint-Louis, Paris

RECRUITING

IUCT-Oncopole, Toulouse

RECRUITING

Institut de Cancerologie Gustave-Roussy, Villejuif